AAV Neutralizing Antibodies: Detection Strategies and Their Impact on Gene Therapy

Gene therapy has emerged as a transformative approach in modern medicine, with Adeno-Associated Virus (AAV) serving as one of the most widely used delivery platforms. AAV vectors are favored for their relatively low pathogenicity, broad tissue tropism, and ability to support long-term gene expression. However, as clinical applications expand, one of the most significant challenges is the presence of AAV neutralizing antibodies (NAbs) in patients. These antibodies can impair vector delivery and reduce therapeutic efficacy, making their detection and characterization a critical component of AAV-based gene therapy development.

Formation of AAV Neutralizing Antibodies

Neutralizing antibodies against AAV arise from prior exposure to naturally occurring wild-type AAV, which is common in the human population. AAV is not known to cause disease, but natural infection can still elicit a humoral immune response.

These antibodies recognize capsid proteins and can:

• Bind to AAV particles and block cellular entry

• Promote clearance of viral particles from circulation

• Interfere with receptor binding or intracellular trafficking

As a result, pre-existing immunity can significantly reduce transduction efficiency. In some cases, even low levels of neutralizing antibodies may be sufficient to inhibit AAV-mediated gene delivery, depending on the serotype and route of administration.

Importance of Neutralizing Antibody Testing

Assessment of anti-AAV immunity has become a standard step in many gene therapy programs, particularly in clinical trial enrollment. Neutralizing antibody testing provides critical information for:

• Patient eligibility screening

• Dose selection and risk assessment

• Interpretation of clinical outcomes

Because AAV vectors are often administered systemically or locally at defined doses, the presence of neutralizing antibodies can lead to reduced efficacy or variability in response across patients. Therefore, understanding a patient’s immune status prior to treatment is essential for optimizing therapeutic success.

Methods for Detecting AAV Neutralizing Antibodies

Several analytical approaches are used to detect and quantify anti-AAV antibodies, each providing different types of information.

Cell-based neutralization assays
These are considered the most functionally relevant assays. In this approach, AAV vectors are incubated with patient serum or plasma and then applied to permissive cells. The degree of inhibition of transgene expression reflects the presence and activity of neutralizing antibodies.

ELISA-based binding assays
Enzyme-linked immunosorbent assays (ELISA) detect antibodies that bind to AAV capsid proteins. While these assays are sensitive and relatively high-throughput, they measure total binding antibodies rather than functional neutralization, and therefore may not fully predict biological impact.

Functional transduction inhibition assays
These assays quantify how effectively AAV-mediated gene delivery is reduced in the presence of antibodies. They are closely related to cell-based assays and are often used to assess potency in immunological contexts.

Each method has advantages and limitations, and in practice, a combination of assays may be used to obtain a comprehensive view of immune status.

Key Challenges and Considerations

Despite advances in assay development, several challenges remain in the field of AAV neutralizing antibody testing:

• Variability between assay formats and laboratories

• Differences in sensitivity depending on AAV serotype and cell model

• Lack of universal standardization for defining positive thresholds

• Potential discrepancies between binding antibody levels and functional inhibition

In addition, the clinical relevance of low-titer antibodies is still an area of active investigation, particularly in the context of different administration routes such as intravenous versus intrathecal delivery.

Strategies to Address Anti-AAV Immunity

To mitigate the impact of neutralizing antibodies, multiple strategies are being explored:

• Pre-treatment screening
  Identifying eligible patients based on antibody status remains the most widely used approach in clinical trials

• Immunomodulation
  Approaches such as transient immunosuppression or antibody depletion are under investigation to reduce immune barriers

• Capsid engineering
  Development of novel AAV variants with reduced recognition by pre-existing antibodies is an active area of research

• Alternative dosing strategies
  Adjusting dose or route of administration may help overcome partial neutralization in some cases

These strategies aim to expand patient eligibility and improve therapeutic consistency.

Future Directions in AAV Immunogenicity and Assay Development

The field is moving toward more standardized and predictive assays for AAV immunity. Advances in high-throughput screening, improved cell models, and better-defined reference standards are expected to enhance assay reproducibility and clinical relevance.

Emerging directions include:

• Development of standardized neutralization assay platforms

• Integration of binding and functional assays for multi-dimensional analysis

• Improved understanding of immune correlates of efficacy

• Expansion of capsid libraries to overcome pre-existing immunity

As knowledge of AAV immunology deepens, these advances will help refine both patient selection and vector design.

Conclusion

Neutralizing antibodies against AAV represent a critical challenge in gene therapy, influencing both efficacy and patient eligibility. Their detection and characterization are essential components of AAV bioanalysis and clinical development.

By combining robust analytical methods with innovative strategies to overcome immune barriers, the field is steadily improving its ability to deliver consistent and effective gene therapies. Continued progress in assay development, capsid engineering, and immunological understanding will further enhance the clinical potential of AAV-based therapeutics.